Gantenerumab for treating early Alzheimer's disease [ID6142]
In development
Reference number: GID-TA11269
Expected publication date: TBC
As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Gantenerumab for treating early Alzheimer's disease [ID6142].
For information, the company have announced that trial did not meet its primary endpoints and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time.
Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.